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Abstract
Gemcitabine is a commonly used antineoplastic agent used to treat a variety of cancers with rarely reported cardiac side ef-
fects. We describe a case of a 67-year-old woman with follicular lymphoma who experienced a rarely reported side effect of
gemcitabine: cardiomyopathy. This case highlights a multiple hit mechanism of myocyte damage that may occur following the
use of multiple cardio-toxic agents despite their administration in doses not associated with cardiotoxicity.
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Introduction
Gemcitabine is a commonly used antineoplastic agent that is
a nucleoside analog and pyrimidine antimetabolite that in-
hibits RNA synthesis.1 It is most commonly used in solid organ
malignancies such as non-small cell lung cancer, and breast,
ovarian, and pancreatic cancer, although is also used in dif-
fuse large B-cell lymphoma in relapsed or refractory elderly
patients.2 It has rare cardiac side effects including acute myo-
cardial infarction, but is not well known to cause
cardiomyopathy.
Case report
A 67-year-old woman with past medical history signiﬁcant for
follicular lymphoma with transformation to diffuse large B
cell lymphoma status post multiple cycles of chemotherapy
complicated by transient left ventricular systolic dysfunction
presented with sensation of throat closing and difﬁculty
breathing upon completion of Cycle 2 of Rituximab plus
Gemcitabine and Oxaliplatin (R-GemOx).
Her follicular lymphoma was initially diagnosed in 2007 and
treated with Rituximab, Cyclophosphamide, Doxorubicin, and
Vincristine (R-CHOP). Prior to initiation of chemotherapy, her
left ventricular ejection fraction (LVEF) was normal. Three years
following treatment with doxorubicin, her LVEF remained
normal. Her only risk factor for cardiovascular disease was
hyperlipidemia (total cholesterol 248mg/dL, LDL 171mg/dL);
with no known hypertension, diabetes, or family history of
coronary disease, and a normal exercise nuclear stress test.
In 2010, her cancer transformed to diffuse large B cell lym-
phoma (DLBCL) requiring autologous stem cell transplant. She
was then treated with Rituximab, Ifosfamide, Carboplatin, and
Etoposide (R-ICE). Her disease remained in remission until
2013. At that time, a left groin biopsy revealed recurrent
DLBCL. She was placed on Bretuximab/Rituximab, but once
her disease progressed on this regimen, she was transitioned
to Rituximab, Dexamethasone, Cytarabine, and platinol
(R-DHAP). One month into treatment with R-DHAP, the
patient’s echocardiogram showed severely depressed LVEF
(25–30%) with global hypokinesis. R-DHAP was discontinued,
and a repeat echocardiogram 3months later showed an
improved LVEF to 35–40% (Figure 1, Table 1). All ejection
fractions were determined by visual estimation.
In October 2014, Rituximab, Gemcitabine, and
Oxaliplatin (R-Gem-Ox) were started. One month later,
the patient presented to the hospital with sensation of
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throat closing and difﬁculty breathing. She was admitted
with suspicion of laryngospasm from Oxaliplatin. Upon fur-
ther questioning, since initiation of R-GemOx, the patient
noted exertional dyspnea and fatigue. She was previously
able to walk three to four laps around her local shopping
mall although now endorsed dyspnea upon ambulation to
the nearby bathroom.
On examination, she was found to have a new oxygen re-
quirement and a 7 pound weight gain. Her jugular venous
pressure was elevated with diminished bibasilar lung sounds
and 2+ pitting edema of the lower extremities. Cardiac
auscultation revealed an S3 gallop and III/VI holosystolic
murmur. Chest X-ray showed bilateral pleural effusions. NT
pro-BNP was noted to be 40 000 with a lactate of 4.2. EKG
demonstrated no acute ST or T wave changes. Transthoracic
echocardiogram revealed an LVEF of 20% with global free
wall hypokinesis and severe mitral regurgitation. The patient
was treated with intravenous furosemide. Her renal function
subsequently improved and lactate normalized. Home dosing
of lisinopril and beta-blocker were reintroduced. Given the
concern for gemcitabine-induced cardiomyopathy, this agent
was discontinued. Repeat echocardiogram 6months later
showed an improved LVEF of 40% and mild mitral
regurgitation.
Discussion
Our patient was exposed to multiple chemotherapy agents
with known cardio-toxicity, and her ejection fraction there-
fore ﬂuctuated throughout the course of her treatment.
Cardiomyocytes, as well as other cell types comprising the
heart, have a limited capacity for repair after sustaining injury
from one agent or another. Perhaps, the most cogent exam-
ple of the multiple hit hypothesis is found in cardiotoxicity
occurring after chemotherapy for HER-2/neu-ampliﬁed breast
cancer. When administered alone, the anti-HER-2/neu
monoclonal antibody trastuzumab is associated with a low in-
cidence of subsequent left ventricular contractile dysfunc-
tion, in the range of 4–6%.3 However, when administered
after an anthracycline-based adjuvant regimen, the incidence
of left ventricular systolic dysfunction is as high as 28%.3 The
most plausible explanation for this ﬁnding is that when
Figure 1 Ejection fraction over time.
Table 1 Chemotherapy agent by year, drug class, and frequency of cardiac adverse event
Date Chemotherapy/treatment regimen Drug class/name Cardiac adverse event Frequency of adverse effect
2003 None
2007 R-CHOPa Anthracycline/donarubicin CHF/LV dysfunction +++
2010 Autologous stem cell
transplant (cytoxan-cardiotoxic)
Alkylating agent/cytoxan
(cyclophosphamide)
Pericarditis/myocarditis
CHF
+
++
05/2011 R-ICEb Biologic agent/rituximab Arrhythmias ++
11/2013 Bretuximab/rituximab Biologic agent/rituximab Arrhythmias ++
05/2014 R-DHAPc (04/2014) Alkylating agents/cisplatin Ischemia
Hypertension
CHF
++
++++
+++
07/2014 None
11/2014 R-GemOxa Pyrimidine analog/gemcitabine Supraventricular
Tachycardia
Ischemia cardiomyopathy
++
++
+
05/2015 None
aRituximab, gemcitabine, oxaliplatin.
bRituximab, ifosfamide, carboplatin, and etoposide.
cRituximab, cyclophosphamide, doxorubicin, and vincristine.
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anthracycline-induced cardiomyocyte injury occurs, the lim-
ited ability of cardiomyocytes to repair this damage is abro-
gated by the subsequent administration of trastuzumab,
which, by inhibiting HER-2/neu-dependent signalling
(including phoshoinositide 3-kinase/Akt) in the cardiomyo-
cyte, inactivates cell survival pathways.
Our patient was initially exposed to doxorubicin at a total
cumulative dose of 450mg/m2. The mechanism of cardio-
toxicity here involves disruption of topoisomerase-II-
mediated DNA repair and generation of oxygen-derived free
radicals.4–7 Serial echocardiograms during several years after
doxorubicin administration showed stable LVEF. The fact that
her LVEF ﬂuctuated, rather than displaying a secular down-
trend, in her later course is more consistent with acute car-
diomyocyte injury following administration of individual
agents, and not with chronic anthracycline-induced left ven-
tricular systolic dysfunction which is irreversible.
Three years after treatment with doxorubicin, the patient
was exposed to cyclophosphamide at the time of her stem
cell transplant. Cyclophosphamide can cause endothelial
and myocyte injury mediated through its toxic metabolic
phosphoramide mustard that leads to DNA crosslinking and
subsequent apoptosis.4 The patient was then exposed to
R-DHAP, of which, cisplatin has been shown to cause conges-
tive heart failure, particularly in the elderly. Its mode of tox-
icity involves crosslinking with purine bases on the DNA and
thus interfering with DNA repair mechanisms, causing DNA
damage and cell apoptosis.4,6
Following cessation of R-DHAP, and prior to initiation of
GemOx, our patient’s LVEF improved to 35–40%. After two
cycles of R-GemOx, her LVEF became severely depressed to
20–25%. Oxaliplatin, although commonly known for many
side effects including laryngospasm (for which the patient
was likely initially referred for hospitalization), peripheral
neuropathy, and ototoxicity, is not associated with cardiomy-
opathy. The co-administration of this agent with intravenous
ﬂuids may have contributed to volume overload. However,
this alone would not explain the abrupt development of
acute kidney injury, lactic acidosis, and pronounced drop in
ejection fraction. The more likely culprit for this was
gemcitabine. Acute kidney injury and lactic acidosis resolved
with intravenous diuresis. Upon cessation of gemcitabine,
the patient’s LVEF improved to 40%, near her baseline prior
to initiation of all chemotherapy agents.
Cardiotoxicity secondary to gemcitabine has rarely been
reported in the literature.
A handful of case reports describe arrhythmias as a side ef-
fect of gemcitabine use. Most of these report supraventricular
tachycardias including atrial ﬁbrillation.8,9 Atrial ﬁbrillation is
typically seen 18–24 h of infusion. This side effect is likely be-
cause of a gemcitabine metabolite, 2′,2′-diﬂuorodeoxyuridine
(diFdU), which has a an equivalent half-life of approximately
18–24 h similar to the time of onset of atrial ﬁbrillation.8,9
Several case reports have demonstrated acute myocardial
infarction acutely post-gemcitabine infection secondary to
drug-induced vascular injury or endothelial damage.10–12
Of all the possible cardiac toxicities, cardiomyopathy ap-
pears to be the least reported. In phase I clinical trials of
gemcitabine use, signiﬁcant reduction in LVEF occurred in
0.2% of patient, whereas 0.4–1.7% of patients developed car-
diac arrhythmias.13 Review of the literature of phase II clinical
trials of approximately 979 patients revealed 0.2% arrhyth-
mias, 0.4% cardiomyopathies, and 0.2% with exudative peri-
carditis.14 In these trials, patients who developed
cardiomyopathies had underlying coronary artery disease,
whereas our patient had no history of coronary disease. Out-
side of clinical trials, gemcitabine-induced cardiomyopathy
has been reported only once in the literature.2 The patient
described was similar to ours. He did not have prior coronary
artery disease or risk factors. As with our described case, the
patient presented with signs and symptoms of congestive
heart failure after the second cycle of gemcitabine for pan-
creatic cancer. The patient’s LVEF at the time of presentation
with symptoms of exertional dyspnea was noted to be
15–20% with ﬁndings of global hypokinesis in addition to
functional mitral regurgitation. Gemcitabine was discontinued,
and two months later an echocardiogram showed recovery of
LVEF to 40% and resolution of mitral regurgitation.
We propose a multiple hit mechanism that ultimately led
to a severely depressed LVEF in our patient. The delayed tox-
icity of doxorubicin, in combination with the direct cytotoxic
effects and apoptosis seen with cyclophosphamide, led to
her initial drop in LVEF.4,15 Subsequent exposure to cisplatin
in May 2014 further damaged DNA repair mechanisms and
quickly depressed our patient’s LVEF to 25%. Upon
discontinuation of cisplatin, her LVEF rapidly improved to
35–40%. It was not until the administration of gemcitabine
in November 2014 that her LVEF once again decreased
to 25%.
The primary message of our report is that the administra-
tion of multiple cytotoxic cancer treatments, each with a
different mechanism of action, can result in major
cardiotoxicity despite being given in doses that for each in-
dividual agent may not be cardiotoxic. In the era of combi-
nation chemotherapy employing multiple chemotherapeutic
drugs, it is important to recognize that an interaction may
exist between the effects of individual agents resulting in
cardiac dysfunction that is either unexpected or more se-
vere than expected.
Conclusions
This case highlights a multiple hit mechanism of cardiomyo-
cyte damage that may occur when employing multiple
cardio-toxic agents in doses that, individually, may not be as-
sociated with cardiotoxicity.
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